Hypertension, SystolicAPCIQ-BPNCT05903950
Air Pollution and Cardiovascular Disease in Qatar: an Interventional Study to Reduce Blood Pressure
A study testing Air cleaners with HEPA filter and Air cleaners without HEPA filter in people with Hypertension, Systolic and Metabolic Syndrome, run by Weill Cornell Medical College in Qatar at 1 site in Qatar.
Trial summary
The main objective is to determine if in-home portable air cleaners provide persistent reductions in PM2.5 exposures and improvements in systolic blood pressure and biochemical parameters over one week in patients with metabolic syndrome or type 2 diabetes residing in Qatar. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Hypertension, Systolic, Metabolic Syndrome, Typ 2 Diabetes
- What is being tested?
- Air cleaners with HEPA filter and Air cleaners without HEPA filter
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteQatar
- Study dates
- 3 Nov 2024to Dec 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 and less than 65 years old
- Living in a single residence (home, apartment) located anywhere in Qatar
- Mild systolic hypertension: screening visit systolic BP 130 to 159 mm Hg (off treatment or taking ≤ 2 BP medications that have been stable without changes during prior one week)
- Either:
- Type 2 diabetes patients (HbA1c > 6.5%) OR Non-type 2 diabetes patients with two or more additional criteria for the metabolic syndrome,
- Waist circumference ≥102 cm if male and ≥88 cm if female
Show all 9Show fewer
- Fasting triglycerides ≥150 mg/dL (or taking a triglyceride-lowering medication)
- HDL-C ≤ 40 mg/dL if male and ≤ 50 mg/dL if female (or taking an HDL-raising medication),
- Fasting glucose ≥100 mg/dL (or taking an antidiabetic medication)
Who cannot join
- Pregnancy (self-reported)
- ≥stage 4 kidney disease (estimated glomerular filtration rate <30 ml/min).
- A medical condition placing the participant at risk from participation (per investigators)
- Expected overnight travel outside their residence during the study
- HEPA filter within the ACs of the residence (self-reported) or individual use of HEPA filter filter
- Unable to comprehend/sign an informed consent
Show all 13Show fewer
- Lung disease requiring oxygen
- Cancer receiving treatment.
- Type 1 diabetes or MODY diabetes
- Screening visit: BP ≥160/100 mm Hg
- Medication changes in the past week. If participants are on medications for high BP or hyperlipidemia, they will need to have had stable therapy for at least one week with no planned changes during the study
- Left upper arm circumference >17 inches as this will make BP levels inaccurate with the home monitor used
- Acute illness or infectious symptoms within the prior 4 weeks.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Qatar1 site, 1 recruiting
- Recruiting
Hamad Medical Corporation
Doha
Jassim Al-Suwaidi, MD, +974 4439 5354, jalsuwaidi@hamad.qa
Charbel Abi Khalil, MD, PhD
About this study
Official title: Air Pollution and Cardiovascular Disease in Qatar: an Interventional Study to Reduce Blood Pressure: the APCIQ-BP Trial
The main objective is to determine if in-home portable air cleaners provide persistent reductions in PM2.5 exposures and improvements in systolic blood pressure and biochemical parameters over one week in patients with metabolic syndrome or type 2 diabetes residing in Qatar.
Read the detailed description
Chronic cardio-metabolic diseases such as hypertension and diabetes contribute disproportionately to global morbidity and mortality and are increasing believed to have multiple environmental influences.
PM2.5 is the fifth leading risk factor for global mortality - largely due to cardiovascular disease (CVD). Reducing personal exposure to air pollution has shown promise in improving key cardiovascular risk factors (blood pressure and insulin resistance) in limited studies, but durability of these effects is not known. Personal air cleaners have been shown to decrease personal exposure to PM2.5 and reduce blood pressure in small studies and may serve as a pragmatic intervention in high-risk patients in whom air pollution is a strong contributor to cardiovascular health.
- Conditions
- Hypertension, Systolic, Metabolic Syndrome, Typ 2 Diabetes
- Being tested
- Air cleaners with HEPA filter, Air cleaners without HEPA filter
- Keywords
- hypertension, metabolic syndrome, air pollution, Type 2 Diabetes
- Medical subject headings
- Isolated Systolic Hypertension, Metabolic Syndrome, Hypertension, Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Air cleaners with HEPA filterDevice
PM 2.5 exposure reduction using in home portable air cleaners fitted with HEPA filters
Air cleaners without HEPA filterDevice
Simulation of PM 2.5 exposure reduction using in home portable air cleaners without HEPA filters.
| Study group | Role | What they receive |
|---|---|---|
| Active mode | Active comparator | In home use of portable air cleaners with a High Efficiency Particulate Air (HEPA) filter for one week. Receives: Device: Air cleaners with HEPA filter |
| Sham mode | Sham comparator | In home use of portable air cleaners without a High Efficiency Particulate Air (HEPA) filter for one week. Receives: Device: Air cleaners without HEPA filter |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Systolic Blood Pressure
Mean change from baseline in systolic blood pressure
Measured: week 1, week 3
Secondary outcomes (2)
Change in Fasting Glycemia
Mean change from baseline in fasting glycemia
Measured: week 4, week 10
Change in Insulin Resistance Index
Mean change from baseline in Insulin Resistance Index
Measured: week 4, week 10
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jun 2023
- Study start3 Nov 2024
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hypertension, SystolicStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Weill Cornell Medical College in Qatar
- Sponsor type
- University, hospital or other
- Collaborators
- Hamad Medical Corporation
- Responsible party
- Sponsor
- Investigators
- Charbel Abi Khalil, MD, Principal investigator, Weill Cornell Medical College in Qatar
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05903950
- Sponsor's protocol ID
- 22-00009
- Acronym
- APCIQ-BP
- Status last verified
- Oct 2026
- First submitted
- 5 Jun 2023
- Last updated
- 23 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data that underlie the results reported in the article, after de-identification (test, tables, figures, and appendices).